Articles tagged with Drug Therapy
The Damon Runyon-St. Jude Pediatric Cancer Research Fellowship aims to address a funding gap for pediatric cancer research. The program supports innovative projects that could significantly impact the diagnosis or treatment of one or more pediatric cancers.
A study published in Nature Cardiovascular Research found that tricaprin improved long-term survival and recovery from heart failure in patients with triglyceride deposit cardiomyovasculopathy. The supplement reversed structural changes and improved heart muscle function, leading to higher survival rates compared to controls.
A study comparing hybrid closed-loop and open-loop systems in young people with type 1 diabetes found that hybrid closed-loop systems offered improved long-term blood sugar values, a lower risk of hypoglycemic coma, but a higher rate of diabetic ketoacidosis. The results suggest that hybrid closed-loop therapies may be beneficial for i...
Researchers at Virginia Tech have developed a way to convert gut bacteria into miniature protein factories that produce and release targeted proteins inside the lower intestine. This breakthrough could potentially treat chronic diseases.
Researchers found that flagellin from the gut disrupts immune checkpoint treatment in ovarian cancer patients. Inhibiting this pathway may enhance clinical outcomes and save lives. The discovery could lead to novel therapies capable of targeting ovarian tumors.
Researchers from the University of Gothenburg have made a breakthrough in understanding the role of protein tau in Alzheimer's disease. By identifying specific amino acid modifications that occur before thread-like fibrils form, scientists hope to develop complementary drugs to combat the disease.
Researchers discovered that mismatch repair genes are critical in eliciting damages to neurons vulnerable to Huntington's disease, triggering downstream pathologies and motor impairment. Targeting these genes may offer novel therapeutic approaches, including improving locomotor and gait deficits and reducing neuronal cell death.
A study investigates the efficacy of EFC as a potential treatment for RA, showing anti-inflammatory effects on fibroblast-like synoviocytes and alleviating disease severity in animal models. The findings highlight the therapeutic potential of PDIs in RA management.
Researchers at Osaka Metropolitan University assessed target genes in canine hepatocellular carcinoma (HCC) to develop molecular targeted therapies. The study identified potential gene targets, including PDGFB, which may improve treatment options for unresectable HCC.
Groundbreaking progress in TB vaccine development and therapeutic innovations offer hope to curb the disease's devastating impact, with multi-antigen vaccines and mRNA-based platforms showing promise.
A new 3D bioprinted gastric cancer model successfully replicates the unique characteristics of individual patients' tissues, predicting drug responses and prognosis with high accuracy. This innovative platform enables rapid evaluation within two weeks, contributing to personalized cancer treatment development.
Researchers have created an immune map for pancreatic cancer, showing why some tumours are more susceptible to macrophage-based therapies. The study identifies potential avenues for improved treatment approaches, including boosting certain cell responses and depleting suppressive immune cells.
Researchers found that glioblastoma stem cells are co-localized with myeloid-derived suppressor cells, promoting tumor growth and aggressiveness. The study identified key molecules, such as IL-6 and IL-8, that attract and activate MDSCs, providing new potential therapeutic targets.
Researchers studied whether transcranial direct current stimulation could enhance constraint-induced movement therapy for post-stroke motor recovery. The study found no significant improvement in motor skills, despite using three doses of electrical stimulation on 129 stroke survivors. Future trials aim to address limitations and impro...
Researchers used AI to find adalimumab as potential treatment for iMCD, a rare disease with poor survival rate and few treatment options. The treatment has shown promising results in saving the life of a patient who was on hospice care.
Researchers successfully reversed existing inguinal hernias in male mice using an anti-estrogen drug, restoring their anatomy without surgery. Human tissue samples also showed identical molecular markers as in the mouse model, suggesting a promising treatment target for inguinal hernia repair.
Researchers at the CNIC have designed a treatment strategy to protect the heart against cardiotoxic effects of anthracyclines, a common class of anticancer drugs. Empagliflozin, an SGLT2 inhibitor, has been shown to preserve cardiac function and metabolism in experimental models.
A new study led by UCL researchers has found that the GLP-1 drug exenatide has no positive impact on movement, symptoms, or brain imaging in people with Parkinson's disease. The trial involved 194 participants and ran for 96 weeks, with no benefits shown in any of these areas.
A new study identified USP5 as an enzyme crucial for breaking down unneeded or damaged proteins in the heart. Low levels of USP5 lead to protein buildup, triggering dilated cardiomyopathy in animal models. Increasing USP5 levels helps clear protein 'junk', improving heart function and reducing disease progression.
PairMap overcomes limitations of traditional methods by introducing intermediate compounds to predict binding affinities with high accuracy. The approach minimizes calculation errors, improves convergence, and reduces computational costs for complex transformations.
Researchers at UCSF used CRISPR gene editing technology to transform ordinary white fat cells into 'beige' fat cells that voraciously consume calories to make heat. Implanted near tumors, these cells outcompeted cancer cells for nutrients, beating back five types of cancer in lab experiments.
Researchers from Japan found that organizational strategies, third-wave techniques, and problem-solving techniques are the most effective components of cognitive–behavioral therapy in treating ADHD. These approaches can help improve planning, prioritization, organization, emotional regulation, and stress management.
The American College of Physicians recommends preventing episodic migraines with monotherapy, including beta-adrenergic blockers and antiseizure medications. However, a comparative effectiveness systematic review found no significant differences in clinical net benefit among treatments.
Researchers developed a computer model called MANAscore to identify tumor-fighting immune cells in lung cancer patients treated with immune checkpoint inhibitors. The three-gene model helped find differences associated with patient response to immunotherapy, including the presence of stem-like memory T cells.
A global study published in JACC found that secondary prevention medications for cardiovascular diseases are underused worldwide, with little improvement over time. Medication use varied by country income level, with lower rates in low-income countries.
Researchers have identified ALPK2 as a potential therapeutic target for treating heart failure with preserved ejection function (HFpEF). The enzyme is believed to prevent stiff heart conditions through regulating the TPM1 gene. This discovery offers new hope for developing treatment options targeting ALPK2.
The study found a significant increase in obesity drug prescriptions from 0.76 million in July 2017 to 1.5 million in February 2024, mirroring rising public online search activity for semaglutide and tirzepatide. This correlation highlights the real-time association between public awareness and prescription trends.
A new trial will test whether taking HMB can improve patients' physical function and quality of life. The BOOST study aims to recruit 124 patients with cirrhosis and measure its effects on liver disease, mental wellbeing, and physical function over 24 weeks.
A review of cell death and aging in cancer research reveals the significance of cellular senescence in promoting cancer growth. The study highlights the potential of various types of programmed cell death, such as necroptosis and pyroptosis, as therapeutic targets against senescent cells.
Researchers at Rice University's Synthesis X Center and MD Anderson Cancer Center are developing a light-induced brain delivery platform to improve drug delivery across the blood-brain barrier for treating brain metastasis. The goal is to enhance survival rates and transform the standard of care for this deadly form of cancer.
The collaboration aims to develop advanced 3D mini-brain models for replicating human brain architecture, enabling researchers to explore neurological diseases and screen drug candidates. The platform offers a high-throughput screening method for rapid testing of potential drug candidates.
A team of scientists developed a computational design tool called SPaDES to create new membrane receptors that outperform natural counterparts. The new receptors were designed by optimizing water-mediated interactions, resulting in higher stability and signaling efficiency.
A cohort study found that insurance plan type and structure play a crucial role in determining access to semaglutide for adults with obesity. The findings suggest that targeted interventions at the insurance level could improve equity in obesity treatment access.
Researchers have identified a key protein called Apex1 as a potential therapeutic target for stopping the immune system from attacking itself. By inhibiting this protein, harmful T cells that cause autoimmune diseases and allergies can be eliminated.
A new study published in Cell reveals significant differences in the immune response of children and adults to cancer, with potential implications for targeted therapies. The research shows that children's tumours are generally less inflammatory and have fewer mutations, making them appear less foreign to their immune system.
A new study demonstrates how fluorescent cholesterol probes can visualize cholesterol in live cells, revealing its role in amyloid plaque formation and cellular signaling. The novel probes have the potential to enhance our understanding of how cholesterol imbalances contribute to neurodegenerative disorders.
Researchers found that inhibiting protein RSK1 reduces inflammation and stops progression of blood cancers like myeloproliferative neoplasms and acute myeloid leukemia. The RSK1 inhibitor is already in clinical trials for breast cancer and shows promise as a treatment for blood cancers.
Dr. Blagosklonny's work introduced a new theory and promoted the use of rapamycin to slow aging and extend healthy life by targeting the mTOR pathway, leading to improved immune responses, heart protection, and potential cancer prevention.
Researchers have discovered a key strategy through which persister cells evade the immune response and resist cancer treatments. Inhibiting an epigenetic mechanism could unlock inflammatory genes and compromise persister cell viability.
A recent NUS Medicine study found that a molecule called DUSP6 plays a major role in helping colorectal cancer grow, with higher levels linked to poorer prognosis and decreased survival. Researchers suggest blocking DUSP6 could lead to new therapies for CRC treatment.
Researchers identified a novel genetic risk factor for SARS-CoV-2 infection, linking a PTPN2 variant to increased ACE2 expression and susceptibility. The study suggests Tofacitinib may mitigate this risk, offering new treatment options for patients at higher genetic risk.
Cerebral vascular malformations (CVMs) are redefined as genetic and molecular-driven conditions, with innovative diagnostic approaches like next-generation sequencing and non-invasive imaging genomics. Targeted therapies, including MEK inhibitors and mTOR inhibitors, offer effective alternatives to traditional surgical methods.
A new study found that Medicare Advantage patients with colorectal cancer are six percentage points less likely to receive a cancer drug compared to those on Traditional Medicare. For non-small cell lung cancer, the pattern was not as clear due to limited low-cost treatment options.
Researchers explore the role of efferocytosis in reducing inflammation and containing injury spread after an ischemic stroke. Efferocytosis may offer a promising therapeutic strategy to promote neural regeneration and minimize brain damage.
Researchers developed a computer model to predict which medication works best for each individual patient with CML. The approach has the potential to improve treatment outcomes for patients who previously relied on stem cell transplantation.
Researchers have identified a 177-gene signature common to metastasis across cancers, allowing for personalized risk assessment and potential therapies. The discovery could lead to broader treatment options, faster drug access, and improved patient outcomes.
Researchers developed a predictive tool using the Florey Dementia Index to forecast onset ages of mild cognitive impairment and Alzheimer's. The validated tool may help prioritize patients for disease-modifying treatments.
Researchers developed a gene therapy approach to treat chronic hypereosinophilia by delivering an anti-human eosinophil antibody via AAV-based gene therapy. The therapy successfully suppressed blood eosinophil levels in mice, showing promise as a potential treatment for the condition.
NRG Oncology has established a new Theranostics Subcommittee to develop a more robust theranostics program within its portfolio. The subcommittee will serve as a resource for research investigators and collaborate with other organizations to enhance the effects of treatment on targeted cancer.
The prevalence of substance use disorder surged during the COVID-19 pandemic, but treatment receipt declined initially due to healthcare disruptions. Treatment rates began to recover in 2022, likely driven by reopened treatment programs and increased telehealth use.
Researchers characterize the mysterious C-terminal domain of dystrophin and its role in stabilizing cellular membranes across various tissues. The study reveals that dystrophin's CT domain interacts differently with two major dystrobrevin isoforms, driving differences in binding affinity and interaction modes.
Researchers from Korea University have developed a groundbreaking technique to transform fibroblasts into mature cardiomyocytes, holding promise for regenerative medicine in treating cardiovascular disease. The method combines fibroblast growth factor 4 (FGF4) with vitamin C to accelerate cell maturation and enhance function.
Researchers at U of T have created SIMPL2, a platform that simplifies detection and improves accuracy of protein-protein interactions. The tool enables the rapid identification of protein interactions, including weak ones, for targeted drug therapies.
A groundbreaking study reveals lithium can restore brain function and alleviate behavioral symptoms in animal models of autism spectrum disorder caused by Dyrk1a gene mutations. Lithium normalizes brain size, restores neural structure and function, and improves social interaction and anxiety behaviors.
A clinical trial showed that an antibody blocking Nogo-A protein improves motor function in patients with incomplete spinal cord injuries. The treatment led to significant improvements in voluntary muscle activation and everyday life functional independence. Further studies are needed to confirm the findings.
A study led by Henry J. Pownall and Khurram Nasir found a strong link between the amount of free cholesterol in HDL and its accumulation in macrophages, which can contribute to heart disease. The researchers aim to develop new diagnostics and treatments for managing heart disease using HDL-free cholesterol as a biomarker.
Nearly 50 ISS National Lab-sponsored payloads splashed down safely on SpaceX’s CRS-31 mission, including research for early cancer detection and neurodegenerative conditions treatments. The investigations leveraged the space station's unique environment to improve life on Earth.
The new therapy significantly improves three-year disease-free survival for children with B-ALL, with 96% being disease-free for at least three years. Blinatumomab is now being used in most patients due to its practice-changing breakthrough, offering improved quality of life and reduced side effects.
The Keck School of Medicine of USC has joined the Ryght Research Network to leverage AI tools and optimize cancer clinical trials. The collaboration aims to offer more clinical trials to patients, build new AI tools, and speed up the development of medical treatments.
Engineered yeast cells can form cooperative groups that perform complex tasks and self-regulate in response to external signals. This approach enables precise production of therapeutic compounds, reducing waste and increasing treatment efficacy.